Financial Data and Key Metrics Changes - First quarter revenue was $210 million, up 5% year-over-year, driven by a 17% increase in the industrial segment revenue [5][17] - Non-GAAP gross margin was 34%, at the high end of guidance, benefiting from a favorable product sales mix [6][20] - Non-GAAP EBITDA was $29 million, up 12% compared to the same quarter last year [7] - Non-GAAP EPS in the first quarter was $0.19, up from $0.10 in the previous year [7][22] Business Line Data and Key Metrics Changes - Medical segment revenue was stable year-over-year at $145 million, while industrial segment revenue increased to $65 million, representing 69% and 31% of total revenues respectively [17] - The industrial segment showed broad-based strength, particularly in cargo security inspection systems and components [9][16] - Demand for X-ray sources and digital detectors in the medical segment remained strong, particularly in high-end CT [7][8] Market Data and Key Metrics Changes - Americas revenue grew 17%, driven by strength in the industrial segment related to cargo systems [18] - EMEA revenue rose 7%, while APAC revenue decreased by 7% year-over-year [18] - Sales volume to China remained steady, contributing 17% of total revenues, indicating resilience in the healthcare market position [18] Company Strategy and Development Direction - The company is focusing on a modality-based approach to enhance customer engagement and drive long-term recurring revenue [12] - Increased collaboration with customers is aimed at addressing complex inspection problems using X-ray imaging in real-time manufacturing [9][12] - The company is investing in innovation and technology integration into next-generation imaging systems, particularly in the medical segment [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the medical segment, indicating that previous headwinds are behind them, with strong demand for CT continuing [30][31] - The industrial segment's order pipeline and customer engagement are strong, particularly in food inspection and security screening [32] - Management noted that customer interactions at RSNA indicated a shift towards new product development and commercialization [15][34] Other Important Information - The company modified its non-GAAP policy to exclude gains and losses from equity method investments, reflecting a strategic shift [19] - Inventory increased by $29 million to $328 million, driven by anticipated demand across the industrial segment [22][23] - The company ended the quarter with cash and marketable securities of $126 million, down $30 million from the previous quarter [23] Q&A Session Summary Question: General outlook for the business - Management indicated optimism about both medical and industrial segments, with strong order activity and customer engagement [29][30] Question: Progress on India operations - Management confirmed that the India factory is operational, producing detectors and tubes, with positive customer feedback regarding local manufacturing [36][37] Question: Guidance for the next quarter - Management provided guidance for revenues between $210 million and $225 million, with non-GAAP EPS expected between $0.15 and $0.25 [24][25] Question: Inventory increase explanation - Management explained that the inventory increase is intentional to prepare for cargo systems ramp-up and qualification cycles for products in India [80][81] Question: Refinancing plans - Management is working on refinancing high-yield debt due in October 2027, aiming to complete it before October 2026 [82][84]

Financial Data and Key Metrics Changes - First quarter revenue was $210 million, up 5% year-over-year, driven by a 17% increase in industrial segment revenue [5][15] - Non-GAAP gross margin was 34%, at the high end of guidance, benefiting from a favorable product sales mix [5][17] - Non-GAAP EBITDA was $29 million, up 12% compared to the same quarter last year [6] - Non-GAAP EPS in the first quarter was $0.19, up from $0.10 in the previous year [6][18] - GAAP gross margin was 33%, down 100 basis points year-over-year [16] Business Line Data and Key Metrics Changes - Medical segment revenue was stable year-over-year at $145 million, while industrial segment revenue increased to $65 million, representing 69% and 31% of total revenues respectively [15] - Medical segment performance was stable, with strong demand for X-ray sources and digital detectors [6][8] - Industrial segment delivered a 17% growth, driven by cargo security inspection systems and components [5][15] Market Data and Key Metrics Changes - Americas revenue grew 17%, driven by strength in the industrial segment [15] - EMEA revenue rose 7%, while APAC revenue decreased by 7% year-over-year [15] - Sales volume to China remained steady, contributing 17% of total revenues [15] Company Strategy and Development Direction - The company is focusing on a modality-based approach to enhance customer engagement and drive long-term recurring revenue [10][11] - Increased collaboration with customers is aimed at addressing complex inspection problems using X-ray imaging [8][10] - The company is investing in innovation and technology integration into next-generation imaging systems [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the medical segment, indicating that previous headwinds are behind them and customer order activity is strong [27] - The industrial segment's order pipeline remains robust, particularly in food inspection and security screening [27] - Management noted that customer engagement at RSNA was significantly more positive compared to previous years, indicating a shift towards new product development [29][30] Other Important Information - The company modified its non-GAAP policy to exclude gains and losses from equity method investments, reflecting a strategic shift [16][17] - Inventory increased by $29 million to $328 million, driven by anticipated demand and qualification cycles for new products [19][72] Q&A Session Summary Question: General outlook for the current environment - Management indicated that headwinds faced in previous years are behind them, with strong order activity in the medical segment and stability in China [27][28] Question: Progress on India operations - Management confirmed that the India factory is operational, producing detectors and tubes, with strong customer interest in locally sourced products [32][34] Question: Guidance for the upcoming quarter - Management provided guidance for Q2 revenues between $210-$225 million and non-GAAP EPS between $0.15-$0.25, citing a conservative approach [21][22] Question: Cargo orders and industrial segment growth - Management noted strong traction in cargo systems, with potential for double-digit growth in the industrial segment, contingent on customer demand [42][45] Question: Inventory increase and future plans - Management explained that the inventory increase is intentional to support cargo systems ramp-up and qualification cycles in India, with plans to normalize inventory levels [70][72] Question: Refinancing plans - Management is working on refinancing high-yield debt due in October 2027, aiming to complete it before October 2026 [73][74]

Core Viewpoint - The report highlights Yirui Technology as a leading domestic digital X-ray detector manufacturer, emphasizing its comprehensive product matrix and significant market share in the global landscape [2][5]. Product and Market Position - Yirui Technology has developed over 100 types of digital X-ray detectors, covering various medical and industrial applications, with a shipment increase from 67,000 units in 2021 to 105,500 units in 2023, representing a compound annual growth rate (CAGR) of over 25% [2]. - The company accounted for 20.09% of the global digital X-ray detector shipments in 2023, with a total global shipment forecast of 525,300 units [2]. Business Expansion and Growth Potential - The company is expanding into the core components and overall solutions market, with projected revenue from core components reaching 126 million yuan in 2024, a year-on-year growth of approximately 45.5% [3]. - The overall solutions segment is expected to generate around 96 million yuan in 2024, reflecting a staggering year-on-year growth of 262.56% [3]. - The company has initiated projects for medical DR, C-arm, and CT products, with an anticipated production value of nearly 5 billion yuan by 2030 [3]. Core Component Market Opportunity - The global tube market is projected to grow from $4.26 billion in 2023 to $9.53 billion by 2030, with a CAGR of 12.18% [4]. - Yirui Technology has begun developing various types of tubes since 2022, with some products nearing mass production and achieving international advanced standards [4]. Financial Projections - Revenue forecasts for Yirui Technology are expected to reach 2.266 billion yuan, 3.100 billion yuan, and 4.133 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 23.7%, 36.8%, and 33.3% [5]. - Net profit projections for the same years are 597 million yuan, 790 million yuan, and 1.044 billion yuan, with growth rates of 28.3%, 32.3%, and 32.2% [5].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company experienced a revenue of 1.83 billion yuan in 2024, a year-over-year decrease of 1.7%, and a net profit attributable to shareholders of 470 million yuan, down 23.4% year-over-year. In Q1 2025, the revenue was 480 million yuan, a decrease of 1.9% year-over-year, while the net profit attributable to shareholders was 140 million yuan, an increase of 2.7% year-over-year [1][2] Performance Summary - In 2024, the company faced pressure on performance due to a slowdown in bidding and fluctuations in demand for new energy testing. However, the company is in a strategic upgrade phase, with ongoing construction projects expected to enhance long-term growth potential. The company is transitioning from a flat detector supplier to a comprehensive imaging solution provider, indicating strong medium to long-term investment value [2][4] - The company launched new medical products, including a 64-row medical CT detector module, and high-end DSA detectors have entered mass production. The new core component business generated revenue of 126 million yuan in 2024, a year-over-year increase of 45.5%, while the comprehensive solutions and technical services business achieved revenue of 86.8 million yuan, a year-over-year increase of 226.3% [2][3] Growth Potential - The company has established overseas sales or customer service platforms in various countries, including the USA, Germany, South Korea, India, Japan, Mexico, Pakistan, Brazil, and South Africa. The company has seen positive growth from major customers, with dental products achieving small batch sales overseas and industrial core components performing well, generating nearly 100 million yuan in revenue [4] - The company is expected to see a gradual recovery in gross margin and a decrease in operating expense ratios as low-margin new products scale up. The operating cash flow for 2024 was 360 million yuan, a year-over-year increase of 5.9% [9][10] Financial Forecasts - The company forecasts revenues of 2.23 billion yuan in 2025, representing a year-over-year growth of 22.01%, and a net profit attributable to shareholders of 599 million yuan, an increase of 28.67% year-over-year. The expected EPS for 2025 is 4.18 yuan, with a current price-to-earnings ratio of 29.7 times [10][12]

Core Viewpoint - The Chinese non-destructive testing (NDT) industry is experiencing significant growth and technological advancement, with domestic companies like Yirui Technology and Rilian Technology leading the way in innovation and market performance [2][9]. Group 1: Domestic Companies' Performance - Yirui Technology invested over 300 million yuan in R&D, achieving international leadership in photon counting detector technology, breaking a 20-year monopoly in medical CT detectors by Western companies [2]. - SanYing Precision reported a 91% increase in net profit, with its self-developed nanoVoxel series micro-CT achieving a resolution of 0.5 microns, effectively replacing imported equipment for major clients and saving over 40% in procurement costs [3]. - Rilian Technology's revenue and net profit both increased by 25%, successfully producing an 180 kV micro-focus X-ray source and enhancing defect detection accuracy to 99.5% with its AI detection system, significantly improving battery inspection efficiency for CATL [4]. Group 2: Technological Innovations - Steel Research Nake's phased array detection system was successfully applied in Baowu Steel's production line, achieving an international-leading automatic detection speed of 200 rods per hour [5]. - Ultrasonic Electronics achieved revenue and profit growth, breaking through 3D full-focus technology, with its wind turbine blade detection system applied to the world's largest 16MW offshore wind turbine, improving detection accuracy by 60% compared to traditional methods [6]. - Duopule developed a liquid-cooled plate water immersion detection system that addresses welding quality issues in electric vehicle batteries, receiving bulk orders from BYD and CATL [7]. - Zhongke Intelligent's self-developed electromagnetic ultrasonic corrosion detection instrument replaced Canadian products in the West-East Gas Pipeline project, achieving 100% localization [8]. Group 3: Market Overview - The NDT service market in China has exceeded 3 trillion yuan, with annual instrument sales surpassing 20 billion yuan. The demand for NDT technology is surging across various sectors, including new energy, semiconductors, aerospace, rail transportation, and life sciences [9]. - Domestic equipment manufacturers are breaking foreign monopolies through technological innovation, becoming the backbone of industry development [9]. Group 4: Upcoming Forum - The "ACCSI 2025 Second Non-Destructive Testing Technology Innovation Development Forum" will be held on May 13, 2025, in Shanghai, gathering top talents from industry, academia, and research to discuss the latest technological advancements and industrial applications [10]. - The forum will feature authoritative reports and discussions on cutting-edge technologies, including X-ray spectroscopy imaging and terahertz imaging technology, providing a platform for deep communication and collaboration [12][13].